Patient-Reported Outcome Of Facial Erythema (PROOF)

PHASE3CompletedINTERVENTIONAL
Enrollment

92

Participants

Timeline

Start Date

July 1, 2013

Primary Completion Date

November 14, 2013

Study Completion Date

November 14, 2013

Conditions
RosaceaErythema
Interventions
DRUG

Brimonidine tartrate was applied cutaneously once daily for 8 days.

DRUG

Brimonidine tartrate vehicle was applied cutaneously once daily for 8 days.

Trial Locations (14)

Unknown

Klinik für Dermatologie, Venerologie und Allergologie, Berlin

Universitätsklinikum Düsseldorf, Düsseldorf

Klinikum der Johann Wolfgang Goethe-Universität, Frankfurt am Main

Universitätsklinikum Münster, Klinik für Hautkrankheiten, Münster

Universitäts-Hautklinik Eberhard Karls Universität Tübingen, Tübingen

CentroDerm Gesellschaft für dermatolgische Forschung mbH (GmbH), Wuppertal

Zentrum für Dermatologie, Allergologie und Dermatochirurgie, Wuppertal

Capio Citykliniken, Lund

Läkarhuset Odenplan, Stockholm

University Hospitals of Leicester, Leicester

Royal Free Hospital, London

Whipps Cross University Hospital, London

Harrogate District Hospital, Yorkshire

DD1 9SY

NHS Tayside, Dundee

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Galderma R&D

INDUSTRY

NCT01885000 - Patient-Reported Outcome Of Facial Erythema (PROOF) | Biotech Hunter | Biotech Hunter